Monitoring molecular residual disease in patients with resected pancreatic cancer
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
This study is testing if tracking cancer DNA in the blood can help doctors make better treatment choices for patients who have had surgery for pancreatic cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05802407 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the prognostic value of molecular residual disease (MRD) monitoring using circulating tumor DNA (ctDNA) in patients who have undergone surgery for pancreatic cancer. Participants will provide peripheral blood samples for MRD testing before starting adjuvant chemotherapy and after the first imaging assessment post-chemotherapy. The study aims to understand how changes in MRD levels can guide treatment decisions and improve patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone curative-intent surgery for ductal adenocarcinoma of the pancreas.
Not a fit: Patients with pancreatic cancer types other than ductal adenocarcinoma or those who have received prior systemic antitumor treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment strategies for patients with resected pancreatic cancer.
How similar studies have performed: While the specific approach of using ctDNA for MRD monitoring in pancreatic cancer is relatively novel, similar methodologies have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection); * both sexes, age ≥18 years old; * ECOG performance status score ≤2; * the expected survival time was ≥3 months. Exclusion Criteria: * a known diagnosis of pancreatic cancer other than ductal adenocarcinoma; * treated with any systemic antitumor treatment before first-line chemotherapy onset; * died or lost to follow-up within one month after the initiation of adjuvant chemotherpay; * combined with other primary malignances.
Where this trial is running
Beijing
- Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Chunmei Bai, MD — Peking Union Medical College Hospital
- Study coordinator: Chunmei Bai, MD
- Email: tangh160706@163.com
- Phone: 010-69158764
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.